Private investment in public equity (PIPE) transactions continue to be an important means of fundraising for publicly traded biopharmaceutical companies while the financial markets continue to recover, even with follow-on public offerings (FOPOs) surging. Biomedtracker data show that the amount of money raised in PIPEs, FOPOs and initial public offerings globally during the first three quarters of 2024 has far outpaced the first three quarters of 2023.
Finance Watch: PIPEs Still Key Even As FOPO Fundraising Climbs
PTC Raises $150m In A PRV Sale
Public Company Edition: Biomedtracker data show the amount of money raised in both PIPEs and follow-on offerings surging in 2024. Olema and Cidara raised $250m and $105m, respectively, in recent private placements, while Spyre and Replimune grossed $200m and $140m in FOPOs.
More from Finance Watch
More from Scrip
• By
The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.
• By
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.